Recombinant Human Prostaglandin D2 receptor 2 (PTGDR2)

What is the primary signaling mechanism of PTGDR2?

PTGDR2 (also known as CRTH2) primarily couples to the G-protein Gαi/o, as demonstrated through functional studies using recombinant PTGDR2 expressed in HEK293(EBNA) cells. Activation of PTGDR2 by PGD2 results in a decrease of intracellular cAMP in a pertussis toxin-sensitive manner, confirming the Gαi/o-coupled mechanism . This distinguishes PTGDR2 from the DP1 receptor (PTGDR1), which primarily couples to Gαs and increases cAMP levels upon activation. Methodologically, this signaling mechanism can be verified through cAMP assays after stimulation with PGD2 and related metabolites, with response inhibited by pertussis toxin pretreatment .

What is the tissue distribution pattern of PTGDR2 expression?

While initially identified in hematopoietic cells, Northern blot analysis has revealed that PTGDR2 is expressed in multiple tissues throughout the body. Expression has been detected in brain, heart, thymus, spleen, and various tissues of the digestive system . Additionally, in situ hybridization studies have confirmed PTGDR2 mRNA expression in human eosinophils, and radioligand binding studies have demonstrated endogenous PTGDR2 expression in eosinophilic cell lines, including butyric acid-differentiated HL-60 and AML 14.3D10 . For researchers, tissue distribution analysis should include both transcript-level assessment (qPCR, Northern blot) and protein-level confirmation (immunohistochemistry, Western blot) to fully characterize PTGDR2 expression patterns.

How does the binding affinity of PGD2 and its metabolites differ between PTGDR2 and PTGDR1?

Equilibrium competition binding assays have revealed distinct affinity profiles between PTGDR2 and PTGDR1. For PTGDR2, the rank order of binding potency is: PGD2 > 13,14-dihydro-15-keto PGD2 > 15-deoxy-Δ12,14-PGJ2 > PGJ2 > Δ12-PGJ2 > 15(S)-15 methyl-PGD2, with Ki values ranging from 2.4 to 34.0 nM . This contrasts significantly with PTGDR1, where the binding potency follows: PGD2 > PGJ2 > Δ12-PGJ2 > 15-deoxy-Δ12,14-PGJ2 >>> 13,14-dihydro-15-keto-PGD2 .

Notably, PGD2 demonstrates higher affinity for PTGDR1 than for PTGDR2, with saturation analysis revealing that the affinity of PGD2 for CRTH2 is eight times less than its affinity for the DP receptor . Methodologically, researchers should use radioligand binding assays with appropriate controls when studying ligand-receptor interactions, as receptor expression levels can influence apparent binding affinities.

How does the PGD2/PTGDR2 signaling pathway affect cancer stem cell regulation?

The PGD2/PTGDR2 signaling pathway plays a crucial role in restricting the self-renewal of cancer stem cells (CSCs), particularly in gastric cancer. Mechanistic studies have revealed that PGD2 inhibits STAT3 phosphorylation and nuclear expression, which is essential for CSC maintenance . Specifically, the inhibitory effect of PGD2 on the expression of CSC markers disappears after mutations are introduced into the STAT3 phosphorylation (Thr705) site .

In experimental models, knocking down L-PTGDS (PGD2 synthase) and PTGDR2 expression in CSC-like cells enhances the expression of CSC markers and increases self-renewal ability. Conversely, direct PGD2 stimulation and L-PTGDS overexpression produce the opposite effect, reducing stemness and self-renewal capacity . The expression of L-PTGDS and PTGDR2 is negatively correlated with gastric cancer CSC markers Sall4 and Lgr5 in gastric cancer tissues .

For researchers investigating this pathway, sphere formation assays and in vivo limiting dilution assays are recommended methodological approaches to assess CSC self-renewal capacity following manipulation of the PGD2/PTGDR2 axis.

What is the potential of PTGDR2 expression as a biomarker in asthma and related conditions?

Transcriptomic analysis has identified PTGDR2 as one of the most differentially overexpressed genes in peripheral blood of asthmatic patients (p-value 2.64 × 10^-6) . This finding has been validated through qPCR studies, where PTGDR2 transcripts were significantly upregulated in asthmatic patients (p < 0.001) .

The upregulation of PTGDR2 is particularly prominent in specific asthma subgroups:

• Allergic asthma

• Asthma with chronic rhinosinusitis with nasal polyposis (CRSwNP)

• Aspirin-exacerbated respiratory disease (AERD)

• Eosinophilic asthma

• Severe persistent asthma

For clinical research applications, PTGDR2 expression analysis should follow MIQE guidelines, including appropriate reference gene selection (e.g., GAPDH or TBP) and efficiency testing (optimal values between 90% and 102%) . ROC curve analysis has demonstrated that PTGDR2 expression levels can effectively differentiate between asthmatic and non-asthmatic subjects, suggesting potential utility as a minimally invasive biomarker for adult asthma molecular phenotyping .

How does PTGDR2 expression correlate with eosinophil counts in different asthma subtypes?

While PTGDR2 expression correlates with eosinophil counts in peripheral blood, this relationship shows distinct patterns across different asthma subtypes. In some subgroups of asthmatic patients, PTGDR2 expression provides additional information beyond what can be determined from blood eosinophil counts alone . This suggests that PTGDR2 expression may reflect aspects of disease pathophysiology that are not captured by standard eosinophil enumeration.

For researchers investigating biomarkers, it is important to note that PTGDR2 remains differentially expressed even after adjusting expression levels through logistic regression with blood cell counts . This indicates that PTGDR2 expression is not merely a proxy for eosinophilia but represents a distinct molecular signature in asthmatic conditions.

Methodologically, multivariate regression analysis adjusting for potential confounding variables (age, sex, IgE, and white blood cell counts) should be employed when analyzing PTGDR2 expression data in relation to eosinophil counts .

What are the sex-specific differences in PTGDR2 signaling and expression?

Sex-specific differences in prostaglandin signaling have been observed in several studies. In particular, the expression of PTGDS (Prostaglandin D synthase) has been found to be upregulated in female dorsal root ganglion (DRG) neurons compared to male neurons . Female mice also exhibit higher levels of PTGDS protein and PGD2 production .

Interestingly, PTGDS blockade produces more intense grimacing in male compared to female mice, suggesting that endogenous PGD2 might reduce nociception in the absence of injury in a sex-dependent manner . Additionally, female mice display more mechanical allodynia and grimacing after PGE2 injection than male mice, further highlighting sex differences in prostaglandin responses .

For researchers investigating sex differences:

• Statistical analysis should account for unequal variances between groups (e.g., using Welch's correction with t-tests)

• Include appropriate age matching and consider hormonal status (e.g., exclude post-menopausal samples when investigating reproductive hormone effects)

• Analyze large neuron populations for statistical power (e.g., the cited study analyzed 6,813 neurons: 2,920 from female DRG samples and 3,893 from male DRG samples)

What methodologies are most effective for studying PTGDR2 expression in clinical samples?

For reliable quantification of PTGDR2 expression in clinical samples, quantitative PCR (qPCR) with appropriate reference genes is the most widely validated approach. The methodology should include:

• RNA extraction with quality control (RNA integrity number assessment)

• Reverse transcription using standardized protocols

• qPCR using SYBR Green or probe-based assays with efficiency testing (acceptable range: 90-102%)

• Reference gene validation (e.g., GAPDH and TBP have shown similar PTGDR2 relative expressions with high correlation: Spearman ρ, 0.783; p < 0.001)

• Triplicate technical replicates with appropriate non-template controls and calibrators

• Data analysis using the 2^(-ΔΔCt) comparative method

To rule out intra-patient variability, PTGDR2 measurements should be performed twice over time in a subset of subjects . All procedures should follow MIQE guidelines to ensure reproducibility and reliability of results.

How might PTGDR2 antagonists be utilized in precision medicine approaches?

Given the upregulation of PTGDR2 in specific asthma subtypes, measuring PTGDR2 expression levels in peripheral blood might assist in selecting patients most likely to respond to PTGDR2 antagonists . This represents a precision medicine approach that could improve treatment outcomes by targeting therapies to the most appropriate patient populations.

The methodology for implementing such an approach would involve:

• Establishing standardized PTGDR2 expression assays suitable for clinical laboratories

• Determining appropriate cutoff values through ROC curve analysis

• Validating the predictive value of PTGDR2 expression for treatment response in prospective clinical trials

• Integrating PTGDR2 expression testing into asthma management algorithms

What experimental models are optimal for studying PTGDR2 in cancer research?

Based on the available research, several experimental models have proven effective for studying PTGDR2 in cancer:

• In vitro models:

  • CSC-like cell populations derived from gastric cancer cell lines

  • Sphere formation assays to assess self-renewal capacity

  • Gene knockdown/overexpression systems to manipulate PTGDR2 and L-PTGDS expression

• In vivo models:

  • Subcutaneous tumor models to assess growth inhibition

  • Peritoneal metastasis models to evaluate effects on liver and mesenteric metastasis

For mechanistic studies, analyzing STAT3 phosphorylation and nuclear translocation following PGD2 treatment provides insights into downstream signaling events. Site-directed mutagenesis of the STAT3 phosphorylation site (Thr705) can be used to confirm the requirement of this residue for PGD2/PTGDR2-mediated effects on CSC marker expression .

Additionally, correlative studies examining the expression of L-PTGDS, PTGDR2, and CSC markers (e.g., Sall4, Lgr5) in patient-derived tumor samples can provide clinically relevant insights into the role of this pathway in human cancer.

What is the relationship between PTGDR2 expression and disease prognosis?

Studies have shown that PGD2 synthase (L-PTGDS) and PTGDR2 expression are lower in gastric cancer tissues than in adjacent normal tissues, and this reduced expression is associated with patient prognosis . The negative correlation between L-PTGDS/PTGDR2 expression and cancer stem cell markers (Sall4 and Lgr5) further suggests a potential prognostic value of PTGDR2 pathway components .

For researchers investigating prognostic biomarkers, methodology should include:

• Large patient cohorts with comprehensive clinical data and adequate follow-up duration

• Multivariate analysis adjusting for established prognostic factors

• Both transcript-level (qPCR, RNAseq) and protein-level (IHC, Western blot) assessment

• Evaluation in independent validation cohorts

What are the optimal conditions for expressing and purifying recombinant human PTGDR2?

For successful expression and purification of recombinant human PTGDR2, researchers should consider:

• Expression system selection:

  • HEK293(EBNA) cells have been successfully used for functional PTGDR2 expression

  • Mammalian expression systems are generally preferred over bacterial systems for maintaining proper folding and post-translational modifications

• Construct design:

  • Addition of purification tags (His, FLAG, etc.) at positions that do not interfere with ligand binding

  • Codon optimization for the chosen expression system

  • Signal sequence optimization for proper membrane targeting

• Purification strategy:

  • Detergent solubilization optimization (type and concentration)

  • Two-step purification approach (e.g., affinity chromatography followed by size exclusion)

  • Quality control through SDS-PAGE, Western blot, and functional binding assays

• Functional validation:

  • Radioligand binding assays to confirm proper folding and ligand recognition

  • cAMP inhibition assays to verify functional coupling to Gαi/o proteins

How can contradictions in PTGDR2 research findings be systematically addressed?

Contradictions in research findings are common in complex biological systems. For PTGDR2 research, systematic approaches to address contradictions include:

• Methodological standardization:

  • Adopt consistent experimental protocols and reporting standards

  • Document detailed experimental conditions that might influence outcomes

• Context consideration:

  • Sex differences may explain contradictory findings, as demonstrated in studies showing sex-specific effects of PGD2 signaling

  • Cell type-specific responses should be considered, as PTGDR2 is expressed in multiple cell types with potentially different signaling outcomes

• Integrated analysis:

  • Meta-analysis of multiple studies to identify consistent patterns

  • Correlation of in vitro findings with in vivo and clinical observations

• Mechanistic investigation:

  • Detailed signaling pathway analysis to identify context-dependent branch points

  • Consideration of receptor heterodimers or cross-talk with other signaling pathways

For experimental pain studies that have produced contradictory findings regarding prostaglandin signaling, sex-aware data analysis has revealed important differences that may explain discrepancies .